2025 AMCP Nexus Congress

BioCryst will attend the 2025 AMCP Nexus Congress from Oct 27-30, 2025.

  • Suprachoroidal avoralstat, a plasma kallikrein inhibitor, stops vascular leakage in a well-established rabbit model
    ASRS | 2025 | DME
  • Burden of Treatment for Pediatric Patients (Aged Less Than 12 Years) With Hereditary Angioedema and Their Caregivers
    HAEA National Summit | 2025 | HAE
  • Patient Perspectives on the Importance of HAE Treatments
    HAEA National Summit | 2025 | HAE
  • HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P
    HAEA National Summit | 2025 | HAE
  • Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results From APeX-P
    EAACI | 2025 | HAE

Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?

Have questions about our company?